These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
968 related articles for article (PubMed ID: 32889241)
1. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241 [TBL] [Abstract][Full Text] [Related]
2. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. Canziani LM; Trovati S; Brunetta E; Testa A; De Santis M; Bombardieri E; Guidelli G; Albano G; Folci M; Squadroni M; Beretta GD; Ciccarelli M; Castoldi M; Lleo A; Aghemo A; Vernile L; Malesci A; Omodei P; Angelini C; Badalamenti S; Cecconi M; Cremonesi A; Selmi C; J Autoimmun; 2020 Nov; 114():102511. PubMed ID: 32713677 [TBL] [Abstract][Full Text] [Related]
4. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience. Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M; J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study. Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218 [TBL] [Abstract][Full Text] [Related]
7. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients. West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350 [TBL] [Abstract][Full Text] [Related]
8. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296 [TBL] [Abstract][Full Text] [Related]
9. Lack of tocilizumab effect on mortality in COVID19 patients. Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534 [TBL] [Abstract][Full Text] [Related]
10. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report. Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T Nephron; 2020; 144(9):459-462. PubMed ID: 32694244 [TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333 [TBL] [Abstract][Full Text] [Related]
13. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19. Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155 [TBL] [Abstract][Full Text] [Related]
14. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160 [TBL] [Abstract][Full Text] [Related]
15. Tocilizumab treatment in COVID-19: A single center experience. Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Wang L; Peng X; Wang ZH; Cai J; Zhou FC Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ; Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Mojtabavi H; Saghazadeh A; Rezaei N Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891 [TBL] [Abstract][Full Text] [Related]
19. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398 [TBL] [Abstract][Full Text] [Related]
20. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS. Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]